Insider Selling: CeriBell, Inc. (NASDAQ:CBLL) CEO Sells 25,000 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 25,000 shares of the company's stock in a transaction that occurred on Monday, July 7th. The stock was sold at an average price of $17.70, for a total transaction of $442,500.00. Following the sale, the chief executive officer directly owned 776,022 shares of the company's stock, valued at approximately $13,735,589.40. This trade represents a 3.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Xingjuan Chao also recently made the following trade(s):

• On Tuesday, June 3rd, Xingjuan Chao sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $17.00, for a total transaction of $425,000.00.
• On Thursday, May 15th, Xingjuan Chao sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $16.96, for a total transaction of $424,000.00.
• On Wednesday, April 23rd, Xingjuan Chao sold 15,628 shares of CeriBell stock. The stock was sold at an average price of $15.11, for a total transaction of $236,139.08.
• On Thursday, April 17th, Xingjuan Chao sold 5,700 shares of CeriBell stock. The stock was sold at an average price of $15.02, for a total transaction of $85,614.00.
• On Monday, April 21st, Xingjuan Chao sold 3,372 shares of CeriBell stock. The shares were sold at an average price of $15.03, for a total transaction of $50,681.16.

CeriBell Stock Down 3.7%

NASDAQ:CBLL traded down $0.63 during midday trading on Wednesday, reaching $16.50. 246,657 shares of the stock traded hands, compared to its average volume of 291,869. The company has a current ratio of 17.36, a quick ratio of 16.81 and a debt-to-equity ratio of 0.11. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $32.75. The company has a fifty day moving average of $17.51 and a 200 day moving average of $19.86.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. The firm had revenue of $20.49 million for the quarter, compared to analysts' expectations of $19.30 million. As a group, equities research analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Institutional Trading of CeriBell

Institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc bought a new stake in CeriBell during the 4th quarter worth approximately $32,000. Summit Investment Advisors Inc. bought a new position in CeriBell in the fourth quarter worth about $33,000. Tower Research Capital LLC TRC purchased a new stake in CeriBell in the 4th quarter worth approximately $37,000. BNP Paribas Financial Markets purchased a new stake in CeriBell in the 4th quarter worth approximately $43,000. Finally, PNC Financial Services Group Inc. purchased a new stake in CeriBell in the 4th quarter worth approximately $47,000.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on CBLL shares. LADENBURG THALM/SH SH initiated coverage on shares of CeriBell in a report on Friday, April 4th. They set a "buy" rating and a $32.00 price target on the stock. BTIG Research initiated coverage on shares of CeriBell in a research report on Tuesday, June 24th. They issued a "buy" rating and a $30.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $32.14.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.